BCL2L10

Across TCGA pan-cancer cohorts, BCL2L10 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of BCL2L10’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where BCL2L10 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BCL2L10 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

LSCC are the cancer types where BCL2L10 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL2L10 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	−1.175	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

BCL2L10–LSCC

Open the LSCC breakdown →